Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women

Patrizia D'Amelio, Anastasia Grimaldi, Stefania Di Bella, Cristina Tamone, S. Z M Brianza, M. G A Ravazzoli, Paola Bernabei, Maria Angela Cristofaro, Gian Piero Pescarmona, Giancarlo Isaia

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

This paper studies the effect of oral risedronate on osteoclast precursors, osteoclast formation, and cytokine production in 25 osteoporotic women. Risedronate is effective in reducing the number of osteoclast precursors, their formation, vitality, and activity and the level of RANKL and TNF-α in cultures. Introduction: Bisphosphonates inhibit bone resorption by acting against osteoclasts. Some in vitro studies suggest that they induce osteoclast apoptosis; others suggest that they exert an effect on the production of pro-osteoclastogenic cytokines. The effect of risedronate on osteoclastogenesis by peripheral blood mononuclear cells (PBMCs) in postmenopausal osteoporosis has not been previously studied. This paper examined the influence of risedronate on the formation of osteoclast precursors and cytokine production within the compass of osteoclastogenesis in osteoporosis. Materials and Methods: This study was conducted on 38 osteoporotic women; 25 patients were treated with risedronate 5 mg/d, whereas 13 were treated with calcium 1 g/d and vitamin D 800 UI/d. The following parameters were assessed: changes in bone turnover, circulating osteoclast precursors, formation of osteoclasts in PBMC cultures, their activity and vitality, and variations in the production of pro-osteoclastogenic cytokines before and after therapy. Results: After 3 mo of risedronate, there was a significant reduction in the number and degree of differentiation of osteoclast precursors, osteoclast formation, vitality and activity, and in the level of RANKL and TNF in cultures and of TNF and osteoprotegerin (OPG) in serum, whereas in the group treated with calcium and vitamin D, there were no significant changes. Conclusions: Our data show that risedronate is effective in lowering the number of circulating osteoclast precursors, their formation, vitality, and activity in cultures, and in reducing the level of pro-osteoclastogenic cytokines in culture supernatants and in serum.

Original languageEnglish
Pages (from-to)373-379
Number of pages7
JournalJournal of Bone and Mineral Research
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Osteoclasts
Cytokines
Osteogenesis
Vitamin D
Blood Cells
Risedronate Sodium
Calcium
Osteoprotegerin
Postmenopausal Osteoporosis
Bone Remodeling
Diphosphonates
Bone Resorption
Serum
Osteoporosis
Cell Culture Techniques
Apoptosis

Keywords

  • Bisphosphonates
  • Cytokines
  • Osteoclast
  • Osteoclast precursor
  • Risedronate

ASJC Scopus subject areas

  • Surgery

Cite this

D'Amelio, P., Grimaldi, A., Di Bella, S., Tamone, C., Brianza, S. Z. M., Ravazzoli, M. G. A., ... Isaia, G. (2008). Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. Journal of Bone and Mineral Research, 23(3), 373-379. https://doi.org/10.1359/jbmr.071031

Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. / D'Amelio, Patrizia; Grimaldi, Anastasia; Di Bella, Stefania; Tamone, Cristina; Brianza, S. Z M; Ravazzoli, M. G A; Bernabei, Paola; Cristofaro, Maria Angela; Pescarmona, Gian Piero; Isaia, Giancarlo.

In: Journal of Bone and Mineral Research, Vol. 23, No. 3, 03.2008, p. 373-379.

Research output: Contribution to journalArticle

D'Amelio, P, Grimaldi, A, Di Bella, S, Tamone, C, Brianza, SZM, Ravazzoli, MGA, Bernabei, P, Cristofaro, MA, Pescarmona, GP & Isaia, G 2008, 'Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women', Journal of Bone and Mineral Research, vol. 23, no. 3, pp. 373-379. https://doi.org/10.1359/jbmr.071031
D'Amelio, Patrizia ; Grimaldi, Anastasia ; Di Bella, Stefania ; Tamone, Cristina ; Brianza, S. Z M ; Ravazzoli, M. G A ; Bernabei, Paola ; Cristofaro, Maria Angela ; Pescarmona, Gian Piero ; Isaia, Giancarlo. / Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. In: Journal of Bone and Mineral Research. 2008 ; Vol. 23, No. 3. pp. 373-379.
@article{8f3ceb1008e841529084a170ae0e97ab,
title = "Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women",
abstract = "This paper studies the effect of oral risedronate on osteoclast precursors, osteoclast formation, and cytokine production in 25 osteoporotic women. Risedronate is effective in reducing the number of osteoclast precursors, their formation, vitality, and activity and the level of RANKL and TNF-α in cultures. Introduction: Bisphosphonates inhibit bone resorption by acting against osteoclasts. Some in vitro studies suggest that they induce osteoclast apoptosis; others suggest that they exert an effect on the production of pro-osteoclastogenic cytokines. The effect of risedronate on osteoclastogenesis by peripheral blood mononuclear cells (PBMCs) in postmenopausal osteoporosis has not been previously studied. This paper examined the influence of risedronate on the formation of osteoclast precursors and cytokine production within the compass of osteoclastogenesis in osteoporosis. Materials and Methods: This study was conducted on 38 osteoporotic women; 25 patients were treated with risedronate 5 mg/d, whereas 13 were treated with calcium 1 g/d and vitamin D 800 UI/d. The following parameters were assessed: changes in bone turnover, circulating osteoclast precursors, formation of osteoclasts in PBMC cultures, their activity and vitality, and variations in the production of pro-osteoclastogenic cytokines before and after therapy. Results: After 3 mo of risedronate, there was a significant reduction in the number and degree of differentiation of osteoclast precursors, osteoclast formation, vitality and activity, and in the level of RANKL and TNF in cultures and of TNF and osteoprotegerin (OPG) in serum, whereas in the group treated with calcium and vitamin D, there were no significant changes. Conclusions: Our data show that risedronate is effective in lowering the number of circulating osteoclast precursors, their formation, vitality, and activity in cultures, and in reducing the level of pro-osteoclastogenic cytokines in culture supernatants and in serum.",
keywords = "Bisphosphonates, Cytokines, Osteoclast, Osteoclast precursor, Risedronate",
author = "Patrizia D'Amelio and Anastasia Grimaldi and {Di Bella}, Stefania and Cristina Tamone and Brianza, {S. Z M} and Ravazzoli, {M. G A} and Paola Bernabei and Cristofaro, {Maria Angela} and Pescarmona, {Gian Piero} and Giancarlo Isaia",
year = "2008",
month = "3",
doi = "10.1359/jbmr.071031",
language = "English",
volume = "23",
pages = "373--379",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women

AU - D'Amelio, Patrizia

AU - Grimaldi, Anastasia

AU - Di Bella, Stefania

AU - Tamone, Cristina

AU - Brianza, S. Z M

AU - Ravazzoli, M. G A

AU - Bernabei, Paola

AU - Cristofaro, Maria Angela

AU - Pescarmona, Gian Piero

AU - Isaia, Giancarlo

PY - 2008/3

Y1 - 2008/3

N2 - This paper studies the effect of oral risedronate on osteoclast precursors, osteoclast formation, and cytokine production in 25 osteoporotic women. Risedronate is effective in reducing the number of osteoclast precursors, their formation, vitality, and activity and the level of RANKL and TNF-α in cultures. Introduction: Bisphosphonates inhibit bone resorption by acting against osteoclasts. Some in vitro studies suggest that they induce osteoclast apoptosis; others suggest that they exert an effect on the production of pro-osteoclastogenic cytokines. The effect of risedronate on osteoclastogenesis by peripheral blood mononuclear cells (PBMCs) in postmenopausal osteoporosis has not been previously studied. This paper examined the influence of risedronate on the formation of osteoclast precursors and cytokine production within the compass of osteoclastogenesis in osteoporosis. Materials and Methods: This study was conducted on 38 osteoporotic women; 25 patients were treated with risedronate 5 mg/d, whereas 13 were treated with calcium 1 g/d and vitamin D 800 UI/d. The following parameters were assessed: changes in bone turnover, circulating osteoclast precursors, formation of osteoclasts in PBMC cultures, their activity and vitality, and variations in the production of pro-osteoclastogenic cytokines before and after therapy. Results: After 3 mo of risedronate, there was a significant reduction in the number and degree of differentiation of osteoclast precursors, osteoclast formation, vitality and activity, and in the level of RANKL and TNF in cultures and of TNF and osteoprotegerin (OPG) in serum, whereas in the group treated with calcium and vitamin D, there were no significant changes. Conclusions: Our data show that risedronate is effective in lowering the number of circulating osteoclast precursors, their formation, vitality, and activity in cultures, and in reducing the level of pro-osteoclastogenic cytokines in culture supernatants and in serum.

AB - This paper studies the effect of oral risedronate on osteoclast precursors, osteoclast formation, and cytokine production in 25 osteoporotic women. Risedronate is effective in reducing the number of osteoclast precursors, their formation, vitality, and activity and the level of RANKL and TNF-α in cultures. Introduction: Bisphosphonates inhibit bone resorption by acting against osteoclasts. Some in vitro studies suggest that they induce osteoclast apoptosis; others suggest that they exert an effect on the production of pro-osteoclastogenic cytokines. The effect of risedronate on osteoclastogenesis by peripheral blood mononuclear cells (PBMCs) in postmenopausal osteoporosis has not been previously studied. This paper examined the influence of risedronate on the formation of osteoclast precursors and cytokine production within the compass of osteoclastogenesis in osteoporosis. Materials and Methods: This study was conducted on 38 osteoporotic women; 25 patients were treated with risedronate 5 mg/d, whereas 13 were treated with calcium 1 g/d and vitamin D 800 UI/d. The following parameters were assessed: changes in bone turnover, circulating osteoclast precursors, formation of osteoclasts in PBMC cultures, their activity and vitality, and variations in the production of pro-osteoclastogenic cytokines before and after therapy. Results: After 3 mo of risedronate, there was a significant reduction in the number and degree of differentiation of osteoclast precursors, osteoclast formation, vitality and activity, and in the level of RANKL and TNF in cultures and of TNF and osteoprotegerin (OPG) in serum, whereas in the group treated with calcium and vitamin D, there were no significant changes. Conclusions: Our data show that risedronate is effective in lowering the number of circulating osteoclast precursors, their formation, vitality, and activity in cultures, and in reducing the level of pro-osteoclastogenic cytokines in culture supernatants and in serum.

KW - Bisphosphonates

KW - Cytokines

KW - Osteoclast

KW - Osteoclast precursor

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=39749153465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749153465&partnerID=8YFLogxK

U2 - 10.1359/jbmr.071031

DO - 10.1359/jbmr.071031

M3 - Article

VL - 23

SP - 373

EP - 379

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -